207 related articles for article (PubMed ID: 34714526)
1. A retrospective analysis of azacitidine treatment for juvenile myelomonocytic leukemia.
Honda Y; Muramatsu H; Nanjo Y; Hirabayashi S; Meguro T; Yoshida N; Kakuda H; Ozono S; Wakamatsu M; Moritake H; Yasui M; Sano H; Manabe A; Sakashita K
Int J Hematol; 2022 Feb; 115(2):263-268. PubMed ID: 34714526
[TBL] [Abstract][Full Text] [Related]
2. Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia.
Hashmi SK; Punia JN; Marcogliese AN; Gaikwad AS; Fisher KE; Roy A; Rao P; Lopez-Terrada DH; Ringrose J; Loh ML; Niemeyer CM; Rau RE
Pediatr Blood Cancer; 2019 Oct; 66(10):e27905. PubMed ID: 31250550
[TBL] [Abstract][Full Text] [Related]
3. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.
Niemeyer CM; Flotho C; Lipka DB; Starý J; Rössig C; Baruchel A; Klingebiel T; Micalizzi C; Michel G; Nysom K; Rives S; Schmugge Liner M; Zecca M; Schönung M; Baumann I; Nöllke P; Benettaib B; Biserna N; Poon J; Simcock M; Patturajan M; Menezes D; Gaudy A; van den Heuvel-Eibrink MM; Locatelli F
Blood Adv; 2021 Jul; 5(14):2901-2908. PubMed ID: 34297046
[TBL] [Abstract][Full Text] [Related]
4. [Successful second allogeneic hematopoietic stem cell transplantation with azacitidine as bridging therapy for relapsed juvenile myelomonocytic leukemia].
Oshiro T; Hyakuna N; Abe H; Hamada S; Nakanishi K
Rinsho Ketsueki; 2023; 64(3):187-192. PubMed ID: 37019671
[TBL] [Abstract][Full Text] [Related]
5. Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group.
Cseh A; Niemeyer CM; Yoshimi A; Dworzak M; Hasle H; van den Heuvel-Eibrink MM; Locatelli F; Masetti R; Schmugge M; Groß-Wieltsch U; Candás A; Kulozik AE; Olcay L; Suttorp M; Furlan I; Strahm B; Flotho C
Blood; 2015 Apr; 125(14):2311-3. PubMed ID: 25838281
[No Abstract] [Full Text] [Related]
6. Azacitidine (Vidaza
Rubio-San-Simón A; van Eijkelenburg NKA; Hoogendijk R; Hasle H; Niemeyer CM; Dworzak MN; Zecca M; Lopez-Yurda M; Janssen JM; Huitema ADR; van den Heuvel-Eibrink MM; Laille EJ; van Tinteren H; Zwaan CM
Paediatr Drugs; 2023 Nov; 25(6):719-728. PubMed ID: 37695474
[TBL] [Abstract][Full Text] [Related]
7. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Flotho C; Sommer S; Lübbert M
Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and treatment of juvenile myelomonocytic leukemia in Slovak Republic: novel approaches.
Fabri O; Horakova J; Bodova I; Svec P; Laluhova Striezencova Z; Bubanska E; Cermak M; Galisova V; Skalicka K; Vaska A; Doczyova D; Panikova A; Sykora T; Adamcakova J; Kolenova A
Neoplasma; 2019 Sep; 66(5):818-824. PubMed ID: 31129971
[TBL] [Abstract][Full Text] [Related]
9. Azacitidine as a bridge to transplantation in juvenile myelomonocytic leukemia.
Takebayashi A; Yamamoto M; Igarashi K; Muramatsu H; Kawasaki Y
Pediatr Int; 2022 Jan; 64(1):e14929. PubMed ID: 35119175
[No Abstract] [Full Text] [Related]
10. Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia.
Hecht A; Meyer J; Chehab FF; White KL; Magruder K; Dvorak CC; Loh ML; Stieglitz E
Pediatr Blood Cancer; 2019 Nov; 66(11):e27948. PubMed ID: 31347788
[TBL] [Abstract][Full Text] [Related]
11. Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation.
Waespe N; Van Den Akker M; Klaassen RJ; Lieberman L; Irwin MS; Ali SS; Abdelhaleem M; Zlateska B; Liebman M; Cada M; Schechter T; Dror Y
Haematologica; 2016 Dec; 101(12):1508-1515. PubMed ID: 27540140
[TBL] [Abstract][Full Text] [Related]
12. Azacitidine for Relapse After Allogeneic Stem Cell Transplantation-Single-Center Study.
Karakulska-Prystupiuk E; Drozd-Sokołowska J; Waszczuk-Gajda A; Stefaniak A; Dwilewicz-Trojaczek J; Kulikowska A; Chmarzyńska-Mróz E; Basak G; Paluszewska M; Boguradzki P; Jędrzejczak W
Transplant Proc; 2018 Sep; 50(7):2212-2217. PubMed ID: 30177138
[TBL] [Abstract][Full Text] [Related]
13. BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia.
Wu Y; Zehnle PMA; Rajak J; Koleci N; Andrieux G; Gallego-Villar L; Aumann K; Boerries M; Niemeyer CM; Flotho C; Bohler S; Erlacher M
Leukemia; 2024 Jan; 38(1):136-148. PubMed ID: 37945692
[TBL] [Abstract][Full Text] [Related]
14. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.
Locatelli F; Algeri M; Merli P; Strocchio L
Expert Rev Hematol; 2018 Feb; 11(2):129-143. PubMed ID: 29279013
[TBL] [Abstract][Full Text] [Related]
15. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
[TBL] [Abstract][Full Text] [Related]
16. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
[TBL] [Abstract][Full Text] [Related]
17. Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7.
Furlan I; Batz C; Flotho C; Mohr B; Lübbert M; Suttorp M; Niemeyer CM
Blood; 2009 Mar; 113(12):2867-8. PubMed ID: 19299654
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes.
Fujimaki K; Miyashita K; Kawasaki R; Tomita N
Eur J Haematol; 2016 Sep; 97(3):228-31. PubMed ID: 26613362
[TBL] [Abstract][Full Text] [Related]
19. Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.
Pasupuleti SK; Chao K; Ramdas B; Kanumuri R; Palam LR; Liu S; Wan J; Annesley C; Loh ML; Stieglitz E; Burke MJ; Kapur R
Mol Ther; 2023 Apr; 31(4):986-1001. PubMed ID: 36739480
[TBL] [Abstract][Full Text] [Related]
20. Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study.
Xu Y; Guo R; Miao M; Zhang G; Lan J; Jin J
Invest New Drugs; 2022 Oct; 40(5):1117-1124. PubMed ID: 35834039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]